

9/7/1 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

008434112

WPI Acc No: 1990-321112/**199043**

Neutralising monoclonal antibodies against human interferon alpha -
prepd. by usual cell fusion then characterisation in neutralisation test
before establishing stable hybridomas

Patent Assignee: AKAD WISSENSCHAFTEN DDR (DEAK)

Inventor: FRITZKE H; MUNSTER H; TONEW M; WISNIEWSKI H G; WOLLWEBER L

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
-----------	------	------	-------------	------	------	------

DD 277087	A	19900321	DD 321978	A	19881121	199043 B
-----------	---	----------	-----------	---	----------	----------

Priority Applications (No Type Date): DD 321978 A 19881121

Abstract (Basic): DD 277087 A

Prodn. of neutralising monoclonal antibodies (MAb) against human interferon (IFN) alpha comprises (1) immunising BALB/c mice with native IFN alpha; (2) fusing spleen cells with myeloma cells; (3) selecting the resulting hybridomas; (4) determination of antigen determinant specificity by ELISA and solid phase bioassay; (5) biological characterisation of the MAb produced by a neutralisation test; (b) cloning and recloning selected hybridomas by micromanipulation of individual cells in a special appts. to establish stable hybridoma lines; (7) cultivating or transplanting the new hybridomas H/B 71C6 or H/B 71E3 (ZIM 0283 and 0284, respectively), and (8) recovering MAb ZIMET B71C6 or B71E3 from the culture supernatant or ascites fluid.

USE/ADVANTAGE - MAb are useful for (1) neutralising biological activity of IFN-alpha in biological or medical research; (2) for immunochemical diagnostic determinations and (3) for immuno-affinity chromatographic purification of IFN-alpha. (3pp Dwg.No.0/0)

Derwent Class: B04; D16

International Patent Class (Additional): C12N-005/02; C12P-021/00